Company Profile
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest News
Hankook iON Race Handles Tokyo's Day-to-Night Transition Across Two Races
Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader
Earnings To Watch: First Commonwealth Financial (FCF) Reports Q2 Results Tomorrow
Oil slips 4% after US, Iran pause fighting over weekend
This Quantum Stock Is a Key Nvidia Partner and Looks Like a Buy Near a 52-Week Low
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.novartis.com |
| Audit Risk | 1 |
| Board Risk | 2 |
| Overall Risk | 1 |
| Market Cap | 241.20B |
| Trailing P/E | 23.54 |
| Forward P/E | 15.83 |
| Dividend Rate | 3.7 |
| Dividend Yield | 2.92% |
| Trailing Annual Div. Rate | 4.67 |
| Trailing Annual Div. Yield | 3.66% |
| Trailing EPS | 5.39 |
| Forward EPS | 8.02 |
| Book Value | 16.25 |
| Price-to-Book | 7.81 |
| Enterprise-to-Revenue | 4.99 |
| Enterprise-to-EBITDA | 12.25 |
| Ex-Dividend Date | 03/10/2026 |
| Dividend Date | 03/13/2025 |
| Earnings Date | 07/21/2026 |
| Earnings Call Date | 07/21/2026 |
| Earnings Average | 2.2 |
| Earnings Low | 2.06 |
| Earnings High | 2.29 |
| Revenue Average | 14.65B |
| Revenue Low | 14.33B |
| Revenue High | 14.86B |